Literature DB >> 35667840

Inertial Gait Sensors to Measure Mobility and Functioning in Hereditary Spastic Paraplegia: A Cross-Sectional Multicenter Clinical Study.

Martin Regensburger1,2, Imke Tabea Spatz3, Malte Ollenschläger3,4, Christine F Martindale4, Philipp Lindeburg5, Zacharias Kohl3,2, Björn Eskofier4, Jochen Klucken3, Rebecca Schüle6,7, Stephan Klebe5, Jürgen Winkler3,2, Heiko Gaßner3,2,8.   

Abstract

BACKGROUND AND OBJECTIVES: Hereditary spastic paraplegia (HSP) causes progressive spasticity and weakness of the lower limbs. As neurological examination and the clinical Spastic Paraplegia Rating Scale (SPRS) are subject to potential patient- and clinician-dependent bias, instrumented gait analysis bears the potential to objectively quantify impaired gait. The aim of the present study was to investigate gait cyclicity parameters by application of a mobile gait analysis system in a cross sectional cohort of HSP patients and a longitudinal fast progressing subcohort.
METHODS: Using wearable sensors attached to the shoes, HSP patients and controls performed a 4x10 meters walking test during regular visits in three outpatient centers. Patients were also rated according to the SPRS and in a subset, questionnaires on quality of life and fear of falling were obtained. An unsupervised segmentation algorithm was employed to extract stride parameters and respective coefficients of variation.
RESULTS: Mobile gait analysis was performed in a total of 112 ambulatory HSP patients and 112 age and gender matched controls. While swing time was unchanged compared to controls, there were significant increases in the duration of the total stride phase and the duration of the stance phase, both regarding absolute values and coefficients of variation values. While stride parameters did not correlate to age, weight or height of the patients, there were significant associations of absolute stride parameters to single SPRS items reflecting impaired mobility (|r| > 0.50), to patients' quality of life (|r| > 0.44), and notably to disease duration (|r| > 0.27). Sensor-derived coefficients of variation, on the other hand, were associated with patient-reported fear of falling (|r| > 0.41) and cognitive impairment (|r| > 0.40). In a small 1-year follow-up analysis of patients with complicated HSP and fast progression, absolute values of mobile gait parameters had significantly worsened compared to baseline. DISCUSSION: The presented wearable sensor system provides parameters of stride characteristics which appear clinically valid to reflect gait impairment in HSP. Due to the feasibility with regard to time, space and costs, the present study forms the basis for larger scale longitudinal and interventional studies in HSP.
© 2022 American Academy of Neurology.

Entities:  

Keywords:  Gait Analysis; Wearables; [163] Gait disorders/ataxia; [174] Spastic paraplegia

Year:  2022        PMID: 35667840      PMCID: PMC9519248          DOI: 10.1212/WNL.0000000000200819

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   11.800


  41 in total

1.  Disease severity affects quality of life of hereditary spastic paraplegia patients.

Authors:  S Klimpe; R Schüle; J Kassubek; S Otto; Z Kohl; S Klebe; T Klopstock; S Ratzka; K Karle; L Schöls
Journal:  Eur J Neurol       Date:  2011-06-01       Impact factor: 6.089

2.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

3.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.

Authors:  J Ware; M Kosinski; S D Keller
Journal:  Med Care       Date:  1996-03       Impact factor: 2.983

4.  The Spastic Paraplegia Rating Scale (SPRS): a reliable and valid measure of disease severity.

Authors:  R Schüle; T Holland-Letz; S Klimpe; J Kassubek; T Klopstock; V Mall; S Otto; B Winner; L Schöls
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

5.  Technical Validation of an Automated Mobile Gait Analysis System for Hereditary Spastic Paraplegia Patients.

Authors:  Christine F Martindale; Nils Roth; Heiko Gasner; Julia List; Martin Regensburger; Bjoern M Eskofier; Zacharias Kohl
Journal:  IEEE J Biomed Health Inform       Date:  2019-08-26       Impact factor: 5.772

Review 6.  The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies.

Authors:  Luis Ruano; Claudia Melo; M Carolina Silva; Paula Coutinho
Journal:  Neuroepidemiology       Date:  2014-03-05       Impact factor: 3.282

7.  Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients.

Authors:  Rebecca Schüle; Sarah Wiethoff; Peter Martus; Kathrin N Karle; Susanne Otto; Stephan Klebe; Sven Klimpe; Constanze Gallenmüller; Delia Kurzwelly; Dorothea Henkel; Florian Rimmele; Henning Stolze; Zacharias Kohl; Jan Kassubek; Thomas Klockgether; Stefan Vielhaber; Christoph Kamm; Thomas Klopstock; Peter Bauer; Stephan Züchner; Inga Liepelt-Scarfone; Ludger Schöls
Journal:  Ann Neurol       Date:  2016-03-11       Impact factor: 10.422

8.  Dual-task decrements in gait: contributing factors among healthy older adults.

Authors:  Jeffrey M Hausdorff; Avraham Schweiger; Talia Herman; Galit Yogev-Seligmann; Nir Giladi
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2008-12       Impact factor: 6.053

Review 9.  Delving into the complexity of hereditary spastic paraplegias: how unexpected phenotypes and inheritance modes are revolutionizing their nosology.

Authors:  Christelle Tesson; Jeanette Koht; Giovanni Stevanin
Journal:  Hum Genet       Date:  2015-03-11       Impact factor: 4.132

10.  Gait phenotypes in paediatric hereditary spastic paraplegia revealed by dynamic time warping analysis and random forests.

Authors:  Irene Pulido-Valdeolivas; David Gómez-Andrés; Juan Andrés Martín-Gonzalo; Irene Rodríguez-Andonaegui; Javier López-López; Samuel Ignacio Pascual-Pascual; Estrella Rausell
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.